I hope the BLA filing raises the SP and locks in a licensing deal like NP is alluding to. More cash could get the colorectal cancer and GvHD trials flowing without an issue. But I’m cautiously optimistic as the decline in SP (per dilution) from $1.50 to .38 has got me accustomed to the slow going of nature of dilution, the FDA, and biotech life.